CeraVe Appears in 97.9% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.

Answer Capsule

In November 2026, CeraVe appeared in 757 of 773 AI answers included in the Dermatologist Recommended Skin Care Brands benchmark (97.93%). It received 582 recommendations (75.29%), with 342 Top 3 placements and 244 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.

Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. The historical results show how the figures changed across available months. Different monthly samples limit those comparisons, and conflicting AI claims require verification before corrections are proposed.

Current AI visibility

Questions This Section Answers

• How do CeraVe mentions, recommendations and placements compare with its Dermatologist Recommended Skin Care Brands peers?

CeraVe recorded 757 mentions (97.93%) and 582 recommendations (75.29%) across 773 answers included in the benchmark. Top 3 placements numbered 342; first-place recommendations numbered 244. Framing among its mentions was 608 positive, 149 neutral and 0 negative.

CeraVe is the brand most often named in this category, and the gap to the next brand is real but not comfortable. Its mentions and recommendations both lead the field, yet the recommendation rate sits well below the mention rate, meaning many answers name CeraVe without endorsing it. That gap is where the commercial opportunity sits.

Placement is the stronger signal. CeraVe appears near the top of shortlists far more often than its rivals, and first-place finishes are a large share of those shortlists. For a dermatologist-recommended brand, being the default answer rather than a passing mention is what shapes a buyer's first choice.

Framing is almost entirely positive or neutral, with no negative wording recorded. That is a healthy base, but it does not by itself convert mentions into endorsements. The agency would build a scorecard that tracks the mention-to-recommendation gap as a standing measure, so improvements in endorsement are visible separately from raw reach.

What changed since last month

Questions This Section Answers

• How did CeraVe counts and coverage differ across the available monthly snapshots?

From October 2026 to November 2026, CeraVe's mention count rose from 745 to 757, while its recommendation count fell from 728 to 582. The recommendation rate was 94.55% and 75.29% respectively.

The November sample shows a clear split: mentions held steady while recommendations and top placements dropped sharply from October. The movement is large enough to matter commercially, because fewer endorsements and fewer top slots mean CeraVe is being named without being chosen.

The monthly samples are separate selections, so the change in answer totals and the change in rates should be read as two observations, not one explanation. A different sample size does not account for the shift in recommendation or placement rates, and the report does not establish a cause.

The practical response is to treat November as a fresh baseline rather than a trend. The agency would compare the next sample against this one on the same measures, and would avoid drawing conclusions from a single month's movement until a second reading confirms the direction.

Step 1. Measure

Questions This Section Answers

• What should the agency measure and verify first for CeraVe?

AI answers contained 8 conflicting claims about CeraVe: 0 critical, 4 high, 3 medium, 1 low. Of these, 4 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

The fact-check list is the most concrete starting point. Eight conflicting claims were recorded about CeraVe, and four of them carry high or critical priority. These are not proof of error by CeraVe or by any publisher; they are claims that need resolving before anyone acts on them.

A visibility comparison would show where CeraVe is named versus where it is endorsed, which helps the client decide whether to invest in reach or in conversion of existing mentions. The two problems call for different work.

The agency would build a baseline scorecard pairing those two views, then attach each disputed claim to an owner and an evidence requirement. That gives the client a prioritized list rather than a general impression of inconsistency.

Step 2. Make the website consistent

Questions This Section Answers

• Which recorded claim differences about CeraVe should be verified before proposed page edits?

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

The disputed claims cluster around pricing for the moisturizing cream and the hydrating cleansers. Both columns in the review table quote AI answers, not verified company facts, so neither figure should be treated as correct until checked against a current primary source.

Some apparent conflicts may dissolve once the date and the specific product variant are pinned down. A price quoted for a different size, pack or period is not necessarily a contradiction, and the entity match has to be confirmed before any correction is considered.

The agency would prepare page briefs only after that verification. Where a page needs updating, the brief would use approved facts and state the product, size and date explicitly, so future answers have less room to diverge.

Step 3. Align the external narrative

Questions This Section Answers

• Which cited third-party pages are relevant to fact review for CeraVe?

These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.

The Wirecutter cleanser review is the most frequently cited page in the captured answers and is linked to several conflicting claims, which makes it the natural first review target. The other listed pages appear less often but still connect to disputes worth checking.

Citation does not establish influence, and a page linked to a conflicting claim is not necessarily its cause. The same answer can touch several pages, so the list is a starting point for review rather than a ranking of blame.

The agency would check each page's current contents against primary sources before making any request. Where a genuine discrepancy exists, the request would be specific and evidence-backed; where the page is already accurate, the outcome would be recorded as no change needed.

Step 4. Optimize priority company pages

Questions This Section Answers

• Which observed CeraVe website pages should receive review briefs?

The company's website was cited 62 times across 34 distinct page addresses; the table shows 8 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.

The eczema page is the most cited company page in the captured answers, followed by the teenage acne routine and the face wash selection guide. These are the pages where approved facts and clear product guidance would do the most work.

Being cited is not the same as accompanying a recommendation, so the briefs should aim at the questions buyers actually ask rather than at citation volume alone. The dermatologist-developed page is notable because it speaks directly to the brand's core claim.

The agency would draft briefs for the priority pages using approved facts, explicit product and size details, and answers to common buyer questions. Existing coverage would be checked first, so new pages are proposed only where a genuine gap exists.

Step 5. Publish around buyer questions

Questions This Section Answers

• Which observed buyer questions support content briefs for CeraVe?

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

The recorded questions are broad category questions: top brands, dermatologist recommendations, best body lotions and gentle cleansers. CeraVe is mentioned in nearly all of them, which suggests the brand is already in the consideration set when buyers ask.

These are answer observations, not search volume or proof of missing content. The useful signal is which questions produce mentions without endorsements, since those are where a clearer, better-evidenced page could help.

The agency would turn the observed questions into content briefs, checking existing pages before proposing anything new. Briefs would answer the question directly, name the relevant products with their sizes, and give the kind of specific guidance that supports an endorsement rather than a passing mention.

Our 90-day action plan

Questions This Section Answers

• How should the agency sequence the proposed CeraVe work and judge completion?

The first month establishes the baseline: a scorecard, a scoped fact-review register and a shortlist of pages and sources. Each record gets an owner, an evidence requirement and a review status, so nothing sits unresolved without accountability.

The second month produces approved page briefs and justified publisher requests. Confirmed edits, no-change decisions, requests and responses are logged separately, which keeps the record honest about what was actually changed versus what was merely asked.

The third month delivers buyer-content briefs and a fresh scorecard. Completed work is recorded separately from measured answer outcomes, and the comparability limits are stated alongside any month-to-month reading. No outcome is guaranteed.

Methodology

Questions This Section Answers

• How are CeraVe answer metrics and citation populations defined?

This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 773 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.

An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.

The wider citation analysis covers 800 captured answers and 5811 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.

Monthly sample coverage:

The answer samples differ between months. These comparisons show how the recorded results changed; they do not establish why they changed.

The visibility rates rest on answers that met the benchmark's inclusion rules, and the exact collection dates for the original answers have not been verified. A company counts as recommended only when an answer endorses it with positive wording; top placements are part of those recommendations, not additional ones.

Answers can name several companies, so company counts cannot be summed to find distinct answers. Sentiment describes answer wording, not customer satisfaction. The wider citation analysis covers more answers than the benchmark, and cited pages and disputed claims still need independent verification.

Monthly samples differ, so comparisons show how recorded results changed, not why.

Our first three priorities

First, resolve the high-priority pricing claims before any page or publisher action. The agency would verify each against current primary sources, confirm the product, size and date, and record a decision for every claim, including no-change outcomes.

Second, brief the eczema and cleanser pages using approved facts and explicit product details. These are the pages most often cited and the ones most likely to shape whether an answer endorses CeraVe or merely names it.

Third, build buyer-question content around the recorded category questions, checking existing coverage first. Alongside this, the scorecard should track the mention-to-recommendation gap, since that gap is the clearest commercial signal in the evidence and the measure most worth watching across the next samples.